BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to fight cancer. Get up to date with the BeiGene solid tumor pipeline and clinical trials.
Jiaoyan Lyu
Poster presented at ASH 2022 describing the results of comprehensive biomarker analyses performed in patients with B-cell malignancies, particularly diffuse large B-cell lymphoma (DLBCL), to examine biomarkers associated with response or resistance to dual BTK and PD-1 inhibition.
A summary of the latest developments from 12 studies in the treatment of NSCLC, gastric cancers and other solid tumors presented at ESMO 2022.